ANI Pharmaceuticals, Inc. is a fully integrated specialty biopharmaceutical company that develops, manufactures, and commercializes branded and generic prescription medications primarily in the United States. The company operates through two main segments: Rare Disease, and Generics, Established Brands, and Other. The Rare Disease segment is a major growth driver, anchored by Purified Cortrophin Gel (repository corticotropin injection), which is used to treat various conditions including rheumatology, nephrology, and neurology disorders, and accounted for approximately 39% of the company's net revenue in fiscal year 2025. The Generics, Established Brands, and Other segment encompasses a broad portfolio of complex generic products, established brands, and contract manufacturing services. ANI leverages its U.S.-based manufacturing facilities in Baudette, Minnesota, and New Jersey to produce oral solid doses, liquids, topicals, and controlled substances. The company's strategic focus involves scaling its high-margin rare disease franchise while utilizing its generics business to generate steady cash flow and maintain manufacturing efficiency. ANI distributes its products primarily through major national wholesalers, specialty pharmacies, retail pharmacy chains, and hospitals.
